2′-fluoronucleosides

Details 2′-fluoronucleosides 2′-fluoronucleosides

2005-06-28

2005-06-28

Riley, Jezia (Department: 1637)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C514S04400A, C536S001110, C536S004100, C536S022100, C536S023100, C536S025300

Reexamination Certificate

active

06911424

ABSTRACT:
A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:whereinBase is a purine or pyrimidine base;R1is OH, H, OR3, N3, CN, halogen, including F, or CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;R2is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R2is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; andR3is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 4000137 (1976-12-01), Dvonch et al.
patent: 4211773 (1980-07-01), Lopez et al.
patent: 4336381 (1982-06-01), Nagata et al.
patent: 4625020 (1986-11-01), Brundidge et al.
patent: 4666892 (1987-05-01), Fox et al.
patent: 4908440 (1990-03-01), Sterzycki et al.
patent: 5034518 (1991-07-01), Montgomery et al.
patent: 5128458 (1992-07-01), Montgomery et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5246924 (1993-09-01), Fox et al.
patent: 5424416 (1995-06-01), Jones et al.
patent: 5426183 (1995-06-01), Kjell et al.
patent: 5446029 (1995-08-01), Eriksson et al.
patent: 5512671 (1996-04-01), Piantadosi et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 5808040 (1998-09-01), Chu et al.
patent: 5817799 (1998-10-01), Marquez et al.
patent: 5886162 (1999-03-01), Kalman et al.
patent: 5905070 (1999-05-01), Schinazi et al.
patent: 6103707 (2000-08-01), Yamada et al.
patent: 6147058 (2000-11-01), Yoshimura et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 6348587 (2002-02-01), Schinazi et al.
patent: 6458773 (2002-10-01), Gosselin et al.
patent: 0292023 (1988-05-01), None
patent: 0 316017 (1989-05-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 409227 (1991-01-01), None
patent: 0463470 (1992-01-01), None
patent: 0357571 (1996-04-01), None
patent: 0839813 (1998-05-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 94/14831 (1994-07-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 96/22778 (1996-08-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 97/28177 (1997-08-01), None
patent: WO 97/37993 (1997-10-01), None
patent: WO 98/18430 (1998-05-01), None
Schinazi , et al., “Selective Inhibition of Human Immunodeficiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl)-1, 3-Oxathiolane-5-yl]Cytosine”Antimicrobial Agents and Chemotherapy, Nov. 1992, pp. 2423-2431.
Marquez, V.E., et al., Nucleosides & Nucleotides, 14(3-5), 555-558 (1995).
Siddiqui Ma et al., Tetrahed. Letters, vol. 39 No. 13 Mar. 26, 1998.
Wantanabe , et al., “Synthesis and Anti-HIV Activity of 2′-“Up”-Fluoro Analogues of Active Anti-Aids Nucleosides 3′-Azido-3′deoxythymidine (AZT) and 2′, 3′- dideoxycytidinee (DDC),”J. Med. Chem.1990, 33, 2145-2150.
Bouffard, D.Y., et al., “Kinetic Studies of 2′,2′-Difluorodeoxycytidine (Gemcitabine) with Purified Human Deoxycytidine Kinase and Cytidine Deaminase,”Biochemical Pharmacology, 45(9):1857-1861 (1993).
Jeong, L.S., et al., “Unanticipated Retention of Configuration in the DAST Fluorination of Deoxy-4′-thiopyrimidine Nucleosides with ‘Up’ Hydroxyl Groups.”Tetrahedron Letters, 35(41):7569-7572 (1994).
Jeong, L.S., et al., “Facile Fluorination of Deoxy-4′-thiopyrimidine Nucleosides with ‘Down’ Hydroxyl Groups. Retention of Configuration After Fluoride Opening of the Quaterized N3-MFM Anhydronucleosides,”Tetrahedron Letters, 35(41):7573-7576 (1994).
Montgomery, J.A., et al., “9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2′-Deoxyguanosine.”J. Med Chem.29(11):2389-2392 (Nov. 1986).
Niihata, S., et al., “Synthesis of 2-Fluoro Sugar and Its Condensation Reaction with Silylated Thymine,”Bull. Chem. Soc. Jpn.68(5):1509-1512 (May 1995).
Okabe, M . et al., “Synthesis of 1-(2,3-Dideoxy-2-fluoro-β-D-threo-pentofuranoxyl)cytosine (F-ddC). A Promising Agent for the Treatment of Acquired Immune Deficiency Syndrome,” J.Org. Chem.56:4392-4397 (Feb. 1991).
Van Aerschot, A., et al., “3′-Fluoro-2′,3′-dideoxy-5-chlorouridine: Most Selective Anti-HIV-1 Agent among a Series of New 2′- and 3′-Fluorinated 2′,3′-Dideoxynucleoside Analogues.”J. Med. Chem.32(8):1743-1749 (Aug. 1989).
Balakrishna, et al., “Inhibition of Hepatitis B. Virus by a Novel L-Nucleoside, 2′-Fluoro-5-Menthyl- -L-arabinofuranosyl Uracil,”Antimicrobial Agents and Chemotherapy, Feb. 1996, pp. 380-356.
Borthwick, et al., “Synthesis and Enzymatic Resolution of Carbocyclic 2′-Ara-fluoro-Guanosine; A Potent New Anti-Herpetic Agent,”J. Chem Soc., Chem. Commun.1988.
Cheng, et al.,Journal of Biological Chemistry, vol. 267(20), pp. 13938-13942 (1992).
Chu, et al., “Use of 2′-Fluoro-5-methyl- -L-arabinofuranosyluracil as a Novel Antiviral Agent for Hepatitis B. Virus and Epstein-Barr Virus”Antimicrobial Agents and Chemotherapy, Apr. 1995 pp. 979-981.
Furman, et al., “The Anti-Hepatitis B. Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers of cis-5-Fluoro-1[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine”Antimicrobial Agents and Chemotherapy, Dec. 1992, pp. 2686-2692.
Machida, H., et al., Antiviral Research, 39 (1998) p. 129-137.
Marquez, V.E., et al., Nucleosides & Nucleotides, 14(3-5), 555558 (1995).
Martin, et al., Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides against Human Immunodeficiency Virus (HIV-1),J. Med., Chem.1990, 33, 2137-2145.
Schinazi, et al., Mutations in retroviral genes associated with drug resistance,International Antiviral News, 1997.
Schinazi, et al., “Selective Inhibition of Human Immunodefiency viruses by Racemates and Enantiomers of cis-5-Fluoro-1-2[Hydroxymethyl)-1, 3-Oxathiolane-5-yl]Cytosine”Antimicrobial Agents and Chemotherapy, Nov. 1992, pp. 2423-2431.
Sterzycki, et al., “Synthesis and Anti-HIV Activity of Several 2′-Fluoro-Containing Pyrimidine Nucleosides,”J. Med. Chem.1990.
Su, T.S., et al., “Synthesis and Antiviral Effects of Several 1-(2-Deoxy-2-fluoro-B-D-arabinofuranosyl)-5-alkyluracils. Some Structure-Activity Relationships,”J. Med. Chem., 1986, 29, 151-154.
Toyota, A., et al., Tetrahedron vol. 51, No. 32, pp. 8783-8798, 1995.
Wantanabe, et al., “Synthesis and Anti-HIV Activity of 2′-“Up”-Fluoro Analogues of Active Anti-Aids Nucleosides 3′-Azido-3′deoxythymidine (AZT) and 2′, 3′-dideoxycytidinee (DDC),”J. Med. Chem.1990, 33, 2145-2150.

Affiliated with

Also associated with

Rating

2′-fluoronucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2′-fluoronucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2′-fluoronucleosides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3466088